Dogwood Therapeutics (DWTX)
NASDAQ:DWTX
Want to see DWTX full AI Analyst Report?
DWTX Stock Chart & Stats
$3.15
-$0.11(-4.15%)
At close: 4:00 PM EST
$3.15
-$0.11(-4.15%)
Day’s Range― - ―
52-Week Range$1.28 - $9.50
Previous CloseN/A
Volume14.38K
Average Volume (3M)1.54M
Market Cap
$50.11M
Enterprise Value-$9.85M
Total Cash (Recent Filing)$13.23M
Total Debt (Recent Filing)$144.93K
Price to Earnings (P/E)―
Beta2.12
Next Earnings
Aug 19, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.60
Shares Outstanding33,629,555
10 Day Avg. Volume77,367
30 Day Avg. Volume1,536,657
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.46
Price to Sales (P/S)0.00
P/FCF Ratio-2.19
Enterprise Value/Market Cap-0.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit570.99
Enterprise Value/Ebitda0.35
Forecast
1Y Price Target
$13.50Price Target Upside328.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.97
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage and a meaningful equity base reduce near-term solvency risk and give the company financial flexibility to fund clinical programs. This balance sheet strength supports partnering, licensing discussions and execution of development milestones before revenue generation.
Clinical Pipeline ProgressDemonstrable enrollment and explicit plans for Phase 3 and manufacturing are durable operational milestones. Progress toward pivotal development materially raises the long-term optionality of advancing a non‑opioid oncology pain therapy to commercialization if trial endpoints and regulatory interactions go as planned.
Non-dilutive And Bridge FundingA recent $12.5M financing plus an NCI grant for SP16 IV reduce immediate dilution and cash pressure. Access to grant funding and targeted raises demonstrates diversified financing that can sustain critical trials and extend runway to key readouts, improving strategic execution prospects.
Bears Say
Pre-revenueThe company remains pre-commercial with zero reported revenue, meaning no internal, recurring cash generation. Long-term viability depends on successful trial outcomes, licensing or commercial launches; absent those, the business must continually access external capital to operate.
Persistent Cash BurnConsistent negative operating cash flow and rapidly deteriorating free cash flow accelerate depletion of resources. Structural cash burn forces recurring financings or partnerships, compresses optionality for parallel programs, and can materially delay or jeopardize development plans if funding tightens.
Dilution & Financing VolatilityShareholder approval enabling large warrant exercise signals reliance on equity-linked financings. This creates a structural dilution risk and highlights funding volatility: future capital needs tied to clinical progress may lead to further equity issuance, diluting long-term returns for existing holders.
Dogwood Therapeutics News
DWTX FAQ
What was Dogwood Therapeutics’s price range in the past 12 months?
Dogwood Therapeutics lowest stock price was $1.28 and its highest was $9.50 in the past 12 months.
What is Dogwood Therapeutics’s market cap?
Dogwood Therapeutics’s market cap is $50.11M.
When is Dogwood Therapeutics’s upcoming earnings report date?
Dogwood Therapeutics’s upcoming earnings report date is Aug 19, 2026 which is in 68 days.
How were Dogwood Therapeutics’s earnings last quarter?
Dogwood Therapeutics released its earnings results on May 14, 2026. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.193 by $0.043.
Is Dogwood Therapeutics overvalued?
According to Wall Street analysts Dogwood Therapeutics’s price is currently Undervalued.
Does Dogwood Therapeutics pay dividends?
Dogwood Therapeutics does not currently pay dividends.
What is Dogwood Therapeutics’s EPS estimate?
Dogwood Therapeutics’s EPS estimate is -0.14.
How many shares outstanding does Dogwood Therapeutics have?
Dogwood Therapeutics has 33,629,555 shares outstanding.
What happened to Dogwood Therapeutics’s price movement after its last earnings report?
Dogwood Therapeutics reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.193. Following the earnings report the stock price went up 6.452%.
Which hedge fund is a major shareholder of Dogwood Therapeutics?
Currently, no hedge funds are holding shares in DWTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dogwood Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.36%
12-Months-Change
Fundamentals
Return on Equity
-35.91%
Trailing 12-Months
Asset Growth
-1.83%
Trailing 12-Months
Company Description
Dogwood Therapeutics
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.
DWTX Stock 12 Month Forecast
Average Price Target
$13.50
▲(328.57% Upside)
Technical Analysis
Marker Therapeutics
―
BioRestorative Therapies
―
Sensei Biotherapeutics
―
Bolt Biotherapeutics
―
Acurx Pharmaceuticals
―
Ownership Overview
73.57% Insiders
0.44% Mutual Funds
9.75% Other Institutional Investors
15.84% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---